CNS Pharmaceuticals (CNSP) Virtual Investor CEO Connect summary

Company overview and strategy

• Focuses on developing drugs for neuro-oncology, specifically targeting glioblastoma with two main programs: berubicin and TPI 287.

• Berubicin is a novel anthracycline designed to cross the blood-brain barrier, with a pivotal trial reading out in the first half of next year.

• TPI 287, a novel abeotaxane, was recently in-licensed after extensive diligence, showing promising results in over 300 patients.

• Both drugs are from established chemotherapy classes but uniquely cross the blood-brain barrier.

• The company has built a robust clinical network and infrastructure to efficiently advance these programs.

Clinical development and trial progress

• The pivotal CNS-201 study for berubicin is in its late stages, with data expected in the first half of next year.

• The trial is multi-center, international, and designed to provide definitive data on overall survival.

• Modifications have been made to improve patient experience and data quality, with a focus on robust, clean endpoints.

• The Data Safety Monitoring Board recommended the trial continue without modification, indicating safety and potential efficacy.

• TPI 287 demonstrated a 60% overall response rate and 13.4-month median survival in prior studies, far exceeding typical outcomes.

Financial position and shareholder value

• Currently trades below cash value, with management viewing the company as deeply undervalued.

• Recent financing actions have secured sufficient cash to complete the pivotal berubicin trial.

• Dilutive measures are taken only as necessary, with a focus on minimizing shareholder impact.

• Full compliance with NASDAQ equity requirements has been achieved, though bid price remains below $1.

• Management, including the CEO, continues to invest personally, expressing strong confidence in the programs.